United Therapeutics (UTHR) Non-Current Debt (2010 - 2024)

United Therapeutics has disclosed Non-Current Debt across 13 years of filings, most recently posting $100.0 million for Q2 2024.

• In Q2 2024, Non-Current Debt fell 87.5% year-over-year to $100.0 million; the TTM figure through Jun 2024 stood at $100.0 million (down 87.5% YoY), while the FY2023 annual figure was $300.0 million, down 62.5% from the prior year.
• Non-Current Debt came in at $100.0 million for Q2 2024 at United Therapeutics, down from $200.0 million in the prior quarter.
• In the past five years, Non-Current Debt ranged from a high of $800.0 million in Q1 2020 to a low of $100.0 million in Q2 2024.
• Average Non-Current Debt over 5 years is $683.3 million, with a median of $800.0 million recorded in 2020.
• Year-over-year, Non-Current Debt surged 33.33% in 2020 and plunged 87.5% in 2024.
• Over 5 years, Non-Current Debt stood at $800.0 million in 2020, then changed by 0.0% to $800.0 million in 2021, then changed by 0.0% to $800.0 million in 2022, then plunged by 62.5% to $300.0 million in 2023, then plunged by 66.67% to $100.0 million in 2024.
• Per Business Quant data, the three most recent Non-Current Debt figures were $100.0 million in Q2 2024, $200.0 million in Q1 2024, and $300.0 million in Q4 2023.